Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2015, Article ID 430596, 9 pages
http://dx.doi.org/10.1155/2015/430596
Review Article

Palmitoylethanolamide, a Natural Retinoprotectant: Its Putative Relevance for the Treatment of Glaucoma and Diabetic Retinopathy

1University of Witten/Herdecke, Alfred-Herrhausen-Straße 50, 58448 Witten, Germany
2Institute of Neuropathic Pain, Vespuccistraat 64-III, 1056 SN Amsterdam, Netherlands
3Università degli Studi del Molise, Via Francesco De Sanctis, No. 1, 86100 Campobasso, Italy
4Faculty of Medicine, Department of Pharmacology and Toxicology, American University of Beirut, P.O. Box 110236, Beirut, Lebanon

Received 26 August 2015; Revised 11 October 2015; Accepted 1 November 2015

Academic Editor: Colin Clement

Copyright © 2015 Jan M. Keppel Hesselink et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Križaj, D. A. Ryskamp, N. Tian et al., “From mechanosensitivity to inflammatory responses: new players in the pathology of glaucoma,” Current Eye Research, vol. 39, no. 2, pp. 105–119, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. V. L. Perez and R. R. Caspi, “Immune mechanisms in inflammatory and degenerative eye disease,” Trends in Immunology, vol. 36, no. 6, pp. 354–363, 2015. View at Publisher · View at Google Scholar
  3. C. E. Gallenga, F. Parmeggiani, C. Costagliola, A. Sebastiani, and P. E. Gallenga, “Inflammaging: should this term be suitable for age related macular degeneration too?” Inflammation Research, vol. 63, no. 2, pp. 105–107, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Semeraro, A. Cancarini, R. dell’Omo, S. Rezzola, M. R. Romano, and C. Costagliola, “Diabetic retinopathy: vascular and inflammatory disease,” Journal of Diabetes Research, vol. 2015, Article ID 582060, 16 pages, 2015. View at Publisher · View at Google Scholar
  5. M. Alhouayek and G. G. Muccioli, “Harnessing the anti-inflammatory potential of palmitoylethanolamide,” Drug Discovery Today, vol. 19, no. 10, pp. 1632–1639, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Schmidt, J. Minnerup, and C. Kleinschnitz, “Emerging neuroprotective drugs for the treatment of acute ischaemic stroke,” Expert Opinion on Emerging Drugs, vol. 18, no. 2, pp. 109–120, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Mergenthaler and A. Meisel, “Do stroke models model stroke?” Disease Models and Mechanisms, vol. 5, no. 6, pp. 718–725, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. J. M. Keppel Hesselink, D. J. Kopsky, and R. F. Witkamp, “Palmitoylethanolamide (PEA)—‘promiscuous’ anti-inflammatory and analgesic molecule at the interface between nutrition and pharma,” PharmaNutrition, vol. 2, no. 1, pp. 19–25, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Costagliola, M. R. Romano, R. Dell'Omo, A. Russo, R. Mastropasqua, and F. Semeraro, “Effect of palmitoylethanolamide on visual field damage progression in normal tension glaucoma patients: results of an open-label six-month follow-up,” Journal of Medicinal Food, vol. 17, no. 9, pp. 949–954, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Strobbe, M. Cellini, and E. C. Campos, “Effectiveness of palmitoylethanolamide on endothelial dysfunction in ocular hypertensive patients: a randomized, placebo-controlled cross-over study,” Investigative Ophthalmology & Visual Science, vol. 54, no. 2, pp. 968–973, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Gagliano, E. Ortisi, L. Pulvirenti et al., “Ocular hypotensive effect of oral palmitoyl-ethanolamide: a clinical trial,” Investigative Ophthalmology and Visual Science, vol. 52, no. 9, pp. 6096–6100, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Pescosolido, A. Librando, M. Puzzono, and M. Nebbioso, “Palmitoylethanolamide effects on intraocular pressure after Nd: YAG laser iridotomy: an experimental clinical study,” Journal of Ocular Pharmacology and Therapeutics, vol. 27, no. 6, pp. 629–635, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Impellizzeri, A. Ahmad, G. Bruschetta et al., “The anti-inflammatory effects of palmitoylethanolamide (PEA) on endotoxin-induced uveitis in rats,” European Journal of Pharmacology, vol. 761, pp. 28–35, 2015. View at Publisher · View at Google Scholar
  14. I. Matias, J. W. Wang, A. S. Moriello, A. Nieves, D. F. Woodward, and V. Di Marzo, “Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 75, no. 6, pp. 413–418, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Pescosolido and M. Puzzono, “First clinical case of effective medical treatment of the vitreoretinal traction with recovery of the visual acuity,” La Clinica Terapeutica, vol. 161, no. 4, pp. e143–e147, 2010. View at Google Scholar · View at Scopus
  16. I. A. S. Rahman, K. Tsuboi, T. Uyama, and N. Ueda, “New players in the fatty acyl ethanolamide metabolism,” Pharmacological Research, vol. 86, pp. 1–10, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Costagliola, R. Dell'Omo, M. R. Romano, M. Rinaldi, L. Zeppa, and F. Parmeggiani, “Pharmacotherapy of intraocular pressure: part I. Parasympathomimetic, sympathomimetic,” Expert Opinion on Pharmacotherapy, vol. 10, no. 16, pp. 2663–2677, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. A. L. Coleman and S. Miglior, “Risk factors for glaucoma onset and progression,” Survey of Ophthalmology, vol. 53, supplement, no. 6, pp. S3–S10, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. I. Soto and G. R. Howell, “The complex role of neuroinflammation in glaucoma,” Cold Spring Harbor Perspectives in Medicine, vol. 4, no. 8, Article ID a017269, 2014. View at Publisher · View at Google Scholar
  20. S. Matsuda, N. Kanemitsu, A. Nakamura et al., “Metabolism of anandamide, an endogenous cannabinoid receptor ligand, in porcine ocular tissues,” Experimental Eye Research, vol. 64, no. 5, pp. 707–711, 1997. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Mikawa, S. Matsuda, T. Kanagawa, T. Tajika, N. Ueda, and Y. Mimura, “Ocular activity of topically administered anandamide in the rabbit,” Japanese Journal of Ophthalmology, vol. 41, no. 4, pp. 217–220, 1997. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Chen, I. Matias, T. Dinh et al., “Finding of endocannabinoids in human eye tissues: implications for glaucoma,” Biochemical and Biophysical Research Communications, vol. 330, no. 4, pp. 1062–1067, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. S. L. Grillo, J. Keereetaweep, M. A. Grillo, K. D. Chapman, and P. Koulen, “N-palmitoylethanolamine depot injection increased its tissue levels and those of other acylethanolamide lipids,” Drug Design, Development and Therapy, vol. 7, pp. 747–752, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Y. Lin, C. W. Lu, C. C. Wu, S. K. Huang, and S. J. Wang, “Palmitoylethanolamide inhibits glutamate release in rat cerebrocortical nerve terminals,” International Journal of Molecular Sciences, vol. 16, no. 3, pp. 5555–5571, 2015. View at Publisher · View at Google Scholar
  25. A. Rahimi, M. Faizi, F. Talebi, F. Noorbakhsh, F. Kahrizi, and N. Naderi, “Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice,” Neuroscience, vol. 290, pp. 279–287, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. M. C. Tomasini, A. C. Borelli, S. Beggiato et al., “Differential effects of palmitoylethanolamide against amyloid-beta induced toxicity in cortical neuronal and astrocytic primary cultures from wild-type and 3xTg-AD mice,” Journal of Alzheimer's Disease, In press.
  27. M. Cipriano, G. Esposito, L. Negro et al., “Palmitoylethanolamide regulates production of pro-angiogenic mediators in a model of β amyloid-induced astrogliosis in vitro,” CNS & Neurological Disorders—Drug Targets, vol. 14, no. 7, pp. 828–837, 2015. View at Publisher · View at Google Scholar
  28. B. E. Cairns, J. C. Laursen, X.-D. Dong, and P. Gazerani, “Intraganglionic injection of a nitric oxide donator induces afferent mechanical sensitization that is attenuated by palmitoylethanolamide,” Cephalalgia, vol. 34, no. 9, pp. 686–694, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. D. De Filippis, A. Russo, D. De Stefano et al., “Palmitoylethanolamide inhibits rMCP-5 expression by regulating MITF activation in rat chronic granulomatous inflammation,” European Journal of Pharmacology, vol. 725, no. 1, pp. 64–69, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. G. M. Raso, A. Santoro, R. Russo et al., “Palmitoylethanolamide prevents metabolic alterations and restores leptin sensitivity in ovariectomized rats,” Endocrinology, vol. 155, no. 4, pp. 1291–1301, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Wang, J. Zheng, A. Kulkarni et al., “Palmitoylethanolamide regulates development of intestinal radiation injury in a mast cell-dependent manner,” Digestive Diseases and Sciences, vol. 59, no. 11, pp. 2693–2703, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Impellizzeri, E. Esposito, R. Di Paola et al., “Palmitoylethanolamide and luteolin ameliorate development of arthritis caused by injection of collagen type II in mice,” Arthritis Research & Therapy, vol. 15, no. 6, article R192, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Esposito, E. Capoccia, F. Turco et al., “Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like receptor 4-dependent PPAR-α activation,” Gut, vol. 63, no. 8, pp. 1300–1312, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. G. M. Raso, R. Simeoli, R. Russo et al., “N-Palmitoylethanolamide protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress,” Pharmacological Research, vol. 76, pp. 67–76, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. I. Paterniti, D. Impellizzeri, R. Di Paola, M. Navarra, S. Cuzzocrea, and E. Esposito, “A new co-ultramicronized composite including palmitoylethanolamide and luteolin to prevent neuroinflammation in spinal cord injury,” Journal of Neuroinflammation, vol. 10, article 91, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Scuderi and L. Steardo, “Neuroglial roots of neurodegenerative diseases: therapeutic potential of palmitoylethanolamide in models of alzheimer's disease,” CNS & Neurological Disorders—Drug Targets, vol. 12, no. 1, pp. 62–69, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Luongo, F. Guida, S. Boccella et al., “Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal glial/microglial phenotypical changes in mice,” CNS & Neurological Disorders—Drug Targets, vol. 12, no. 1, pp. 45–54, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. I. Bettoni, F. Comelli, A. Colombo, P. Bonfanti, and B. Costa, “Non-neuronal cell modulation relieves neuropathic pain: efficacy of the endogenous lipid palmitoylethanolamide,” CNS and Neurological Disorders: Drug Targets, vol. 12, no. 1, pp. 34–44, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. I. Paterniti, D. Impellizzeri, R. Crupi et al., “Molecular evidence for the involvement of PPAR-delta and PPAR-gamma in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma,” Journal of Neuroinflammation, vol. 10, article 20, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. R. Citraro, E. Russo, F. Scicchitano et al., “Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor activation in a genetic model of absence epilepsy,” Neuropharmacology, vol. 69, pp. 115–126, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. E. Esposito, I. Paterniti, M. Campolo, M. Cordaro, and S. Cuzzocrea, “The association of palmitoylethanolamide with luteolin reduces neurotoxicity and apoptosis in amyloid-beta stressed hippocampal organotypic slice cultures,” in The Role of Pharmacological Research for the Growth and Health, Pharmacology CotISo, Ed., Council of the Italian Society of Pharmacology, Turin, Italy, 2013. View at Google Scholar
  42. R. Di Paola, D. Impellizzeri, P. Mondello et al., “Palmitoylethanolamide reduces early renal dysfunction and injury caused by experimental ischemia and reperfusion in mice,” Shock, vol. 38, no. 4, pp. 356–366, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. E. Esposito, D. Impellizzeri, E. Mazzon, I. Paterniti, and S. Cuzzocrea, “Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson's disease,” PLoS ONE, vol. 7, no. 8, Article ID e41880, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Ahmad, R. Crupi, D. Impellizzeri et al., “Administration of palmitoylethanolamide (PEA) protects the neurovascular unit and reduces secondary injury after traumatic brain injury in mice,” Brain, Behavior, and Immunity, vol. 26, no. 8, pp. 1310–1321, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. E. Esposito, I. Paterniti, E. Mazzon et al., “Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury,” Brain, Behavior, and Immunity, vol. 25, no. 6, pp. 1099–1112, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. T. Genovese, E. Esposito, E. Mazzon et al., “Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury,” The Journal of Pharmacology and Experimental Therapeutics, vol. 326, no. 1, pp. 12–23, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Kumar, Z. Qiao, P. Kumar, and Z.-H. Song, “Effects of palmitoylethanolamide on aqueous humor outflow,” Investigative Ophthalmology & Visual Science, vol. 53, no. 8, pp. 4416–4425, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. G. Duff, A. Argaw, B. Cecyre et al., “Cannabinoid receptor CB2 modulates axon guidance,” PLoS ONE, vol. 8, no. 8, Article ID e70849, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. J. E. Slusar, E. A. Cairns, A.-M. Szczesniak, H. B. Bradshaw, A. Di Polo, and M. E. M. Kelly, “The fatty acid amide hydrolase inhibitor, URB597, promotes retinal ganglion cell neuroprotection in a rat model of optic nerve axotomy,” Neuropharmacology, vol. 72, pp. 116–125, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. G. Krishnan and N. Chatterjee, “Endocannabinoids alleviate proinflammatory conditions by modulating innate immune response in muller glia during inflammation,” Glia, vol. 60, no. 11, pp. 1629–1645, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. N. Sepe, L. De Petrocellis, F. Montanaro, G. Cimino, and V. Di Marzo, “Bioactive long chain N-acylethanolamines in five species of edible bivalve molluscs: possible implications for mollusc physiology and sea food industry,” Biochimica et Biophysica Acta, vol. 1389, no. 2, pp. 101–111, 1998. View at Publisher · View at Google Scholar · View at Scopus
  52. V. di Marzo and S. D. Skaper, “Palmitoylethanolamide: biochemistry, pharmacology and therapeutic use of a pleiotropic anti-inflammatory lipid mediator,” CNS & Neurological Disorders—Drug Targets, vol. 12, no. 1, pp. 4–7, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. J. M. Keppel Hesselink, “New targets in pain, non-neuronal cells, and the role of palmitoylethanolamide,” The Open Pain Journal, vol. 5, no. 1, pp. 12–23, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. J. M. Keppel Hesselink, “Chronic idiopathic axonal neuropathy and pain, treated with the endogenous lipid mediator palmitoylethanolamide: a case collection,” International Medical Case Reports Journal, vol. 6, no. 1, pp. 49–53, 2013. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Truini, A. Biasiotta, G. Di Stefano et al., “Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy,” CNS & Neurological Disorders—Drug Targets, vol. 10, no. 8, pp. 916–920, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. F. A. Kuehl, T. A. Jacob, O. H. Ganley, R. E. Ormond, and M. A. P. Meisinger, “The identification of N-(2-hydroxyethyl)-palmitamide as a naturally occurring anti-inflammatory agent,” Journal of the American Chemical Society, vol. 79, no. 20, pp. 5577–5578, 1957. View at Publisher · View at Google Scholar · View at Scopus
  57. F. Perlik, J. Elis, H. Rakovfi et al., “Controlled clinical trial with PEA in children institutions,” Cs Fysiol, vol. 18, pp. 345–346, 1969. View at Google Scholar
  58. K. Mašek, F. Perlík, J. Klíma, and R. Kahlich, “Prophylactic efficacy of N-2-hydroxyethyl palmitamide (Impulsin) in acute respiratory tract infections,” European Journal of Clinical Pharmacology, vol. 7, no. 6, pp. 415–419, 1974. View at Publisher · View at Google Scholar · View at Scopus
  59. J. M. Keppel Hesselink, T. de Boer, and R. F. Witkamp, “Palmitoylethanolamide: a natural body-own anti-inflammatory agent, effective and safe against influenza and common cold,” International Journal of Inflammation, vol. 2013, Article ID 151028, 8 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. D. E. Epps, P. C. Schmid, V. Natarajan, and H. H. O. Schmid, “N-acylethanolamine accumulation in infarcted myocardium,” Biochemical and Biophysical Research Communications, vol. 90, no. 2, pp. 628–633, 1979. View at Publisher · View at Google Scholar · View at Scopus
  61. V. Natarajan, P. C. Schmid, P. V. Reddy, M. L. Zuzarte-Augustin, and H. H. Schmid, “Biosynthesis of N-acylethanolamine phospholipids by dog brain preparations,” Journal of Neurochemistry, vol. 41, no. 5, pp. 1303–1312, 1983. View at Publisher · View at Google Scholar · View at Scopus
  62. V. Natarajan, P. C. Schmid, P. V. Reddy, M. L. Zuzarte-Augustin, and H. H. O. Schmid, “Occurrence of N-acylethanolamine phospholipids in fish brain and spinal cord,” Biochimica et Biophysica Acta, vol. 835, no. 3, pp. 426–433, 1985. View at Publisher · View at Google Scholar · View at Scopus
  63. A. Leon, A. Buriani, R. Dal Toso et al., “Mast cells synthesize, store, and release nerve growth factor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 9, pp. 3739–3743, 1994. View at Publisher · View at Google Scholar · View at Scopus
  64. J. M. Keppel Hesselink, “Evolution in pharmacologic thinking around the natural analgesic palmitoylethanolamide: from nonspecific resistance to PPAR-α agonist and effective nutraceutical,” Journal of Pain Research, vol. 6, pp. 625–634, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. L. Aloe, A. Leon, and R. Levi-Montalcini, “A proposed autacoid mechanism controlling mastocyte behaviour,” Agents and Actions, vol. 39, pp. C145–C147, 1993. View at Publisher · View at Google Scholar · View at Scopus
  66. F. Abramo, L. Campora, F. Albanese et al., “Increased levels of palmitoylethanolamide and other bioactive lipid mediators and enhanced local mast cell proliferation in canine atopic dermatitis,” BMC Veterinary Research, vol. 10, article 21, 2014. View at Publisher · View at Google Scholar · View at Scopus
  67. J. LoVerme, G. La Rana, R. Russo, A. Calignano, and D. Piomelli, “The search for the palmitoylethanolamide receptor,” Life Sciences, vol. 77, no. 14, pp. 1685–1698, 2005. View at Publisher · View at Google Scholar · View at Scopus
  68. J. Lo Verme, J. Fu, G. Astarita et al., “The nuclear receptor peroxisome proliferator-activated receptor-α mediates the anti-inflammatory actions of palmitoylethanolamide,” Molecular Pharmacology, vol. 67, no. 1, pp. 15–19, 2005. View at Publisher · View at Google Scholar · View at Scopus
  69. G. G. Muccioli and N. Stella, “Microglia produce and hydrolyze palmitoylethanolamide,” Neuropharmacology, vol. 54, no. 1, pp. 16–22, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. D. Baker, G. Pryce, J. L. Croxford et al., “Endocannabinoids control spasticity in a multiple sclerosis model,” The FASEB Journal, vol. 15, no. 2, pp. 300–302, 2001. View at Google Scholar · View at Scopus
  71. R. di Paola, D. Impellizzeri, A. Torre et al., “Effects of palmitoylethanolamide on intestinal injury and inflammation caused by ischemia-reperfusion in mice,” Journal of Leukocyte Biology, vol. 91, no. 6, pp. 911–920, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Assaw, A. Bennett, V. Chapman, J. Burston, and G. Hathway, “The role of N-palmitoylethanolamide in inhibition of the carrageenan induced inflammatory pain response,” in Proceedings of the 8th ‘Pain In Europe’ Congress (EFIC '13), Florence, Italy, October 2013.
  73. K. Kono, Y. Kamijo, K. Hora et al., “PPARα attenuates the proinflammatory response in activated mesangial cells,” American Journal of Physiology—Renal Physiology, vol. 296, no. 2, pp. F328–F336, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. Y. Matsushita, D. Ogawa, J. Wada et al., “Activation of peroxisome proliferator-activated receptor δ inhibits streptozotocin-induced diabetic nephropathy through anti-inflammatory mechanisms in mice,” Diabetes, vol. 60, no. 3, pp. 960–968, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. S. Cerrato, P. Brazis, M. F. della Valle, A. Miolo, and A. Puigdemont, “Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFα release from canine skin mast cells,” Veterinary Immunology and Immunopathology, vol. 133, no. 1, pp. 9–15, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. G. Mattace Raso, R. Russo, A. Calignano, and R. Meli, “Palmitoylethanolamide in CNS health and disease,” Pharmacological Research, vol. 86, pp. 32–41, 2014. View at Publisher · View at Google Scholar · View at Scopus
  77. G. D'Agostino, R. Russo, C. Avagliano, C. Cristiano, R. Meli, and A. Calignano, “Palmitoylethanolamide protects against the amyloid-Β25-35-induced learning and memory impairment in mice, an experimental model of alzheimer disease,” Neuropsychopharmacology, vol. 37, no. 7, pp. 1784–1792, 2012. View at Publisher · View at Google Scholar · View at Scopus
  78. M. M. Nentwich and M. W. Ulbig, “Diabetic retinopathy—ocular complications of diabetes mellitus,” World Journal of Diabetes, vol. 6, no. 3, pp. 489–499, 2015. View at Publisher · View at Google Scholar
  79. E. Lontchi-Yimagou, E. Sobngwi, T. E. Matsha, and A. P. Kengne, “Diabetes mellitus and inflammation,” Current Diabetes Reports, vol. 13, no. 3, pp. 435–444, 2013. View at Publisher · View at Google Scholar · View at Scopus
  80. C. Costagliola, V. Romano, M. De Tollis et al., “TNF-alpha levels in tears: a novel biomarker to assess the degree of diabetic retinopathy,” Mediators of Inflammation, vol. 2013, Article ID 629529, 6 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  81. Y. Yu, H. Chen, and S. B. Su, “Neuroinflammatory responses in diabetic retinopathy,” Journal of Neuroinflammation, vol. 12, no. 1, article 141, 2015. View at Publisher · View at Google Scholar
  82. C. M. McVicar, M. Ward, L. M. Colhoun et al., “Role of the receptor for advanced glycation endproducts (RAGE) in retinal vasodegenerative pathology during diabetes in mice,” Diabetologia, vol. 58, no. 5, pp. 1129–1137, 2015. View at Publisher · View at Google Scholar · View at Scopus
  83. K. K. Zhou, S. Benyajati, Y. Le, R. Cheng, W. Zhang, and J.-X. Ma, “Interruption of Wnt signaling in müller cells ameliorates ischemia-induced retinal neovascularization,” PLoS ONE, vol. 9, no. 10, Article ID e108454, 2014. View at Publisher · View at Google Scholar · View at Scopus
  84. X. Chen, H. Zhou, Y. Gong, S. Wei, and M. Zhang, “Early spatiotemporal characterization of microglial activation in the retinas of rats with streptozotocin-induced diabetes,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 253, no. 4, pp. 519–525, 2015. View at Publisher · View at Google Scholar
  85. Y. Liu, M. Costa, and C. Gerhardinger, “IL-1β is upregulated in the diabetic retina and retinal vessels: cell-specific effect of high glucose and IL-1β autostimulation,” PLoS ONE, vol. 7, no. 5, Article ID e36949, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. A. Énzsöly, A. Szabó, K. Szabó, Á. Szél, J. Németh, and Á. Lukáts, “Novel features of neurodegeneration in the inner retina of early diabetic rats,” Histology and Histopathology, vol. 30, no. 8, pp. 971–985, 2015. View at Publisher · View at Google Scholar
  87. U. Rajamani and I. Jialal, “Hyperglycemia induces Toll-like receptor-2 and -4 expression and activity in human microvascular retinal endothelial cells: implications for diabetic retinopathy,” Journal of Diabetes Research, vol. 2014, Article ID 790902, 15 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  88. H. Wang, H. Shi, J. Zhang et al., “Toll-like receptor 4 in bone marrow-derived cells contributes to the progression of diabetic retinopathy,” Mediators of Inflammation, vol. 2014, Article ID 858763, 7 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  89. K. Singh, S. Kant, V. K. Singh, N. K. Agrawal, S. K. Gupta, and K. Singh, “Toll-like receptor 4 polymorphisms and their haplotypes modulate the risk of developing diabetic retinopathy in type 2 diabetes patients,” Molecular Vision, vol. 20, pp. 704–713, 2014. View at Google Scholar · View at Scopus